Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial
Judy E. Garber, D. Cameron, C. Campbell, G. Yothers et autres
us, gb, sg, be, pl, es, fr, tw, se, de, it, kr, jp, ch, is, ar, au, at, ca, nl, cn, ie (code pays fourni par la source)
0 citations
Annals of Oncology